AA
CHRS icon

AlphaCentric Advisors’s Coherus Oncology CHRS Stock Holding History

AlphaCentric Advisors’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-330,000
Closed -$343K – 223
2024
Q3 		$343K Sell
330,000
-670,000
-67% -$919K 0.26% 101
2024
Q2 		$1.73M Hold
1,000,000
– – 1.27% 21
2024
Q1 		$2.39M Hold
1,000,000
– – 1.44% 17
2023
Q4 		$3.33M Buy
1,000,000
+87,500
+10% +$234K 2.24% 8
2023
Q3 		$3.41M Hold
912,500
– – 1.94% 8
2023
Q2 		$3.9M Buy
912,500
+558,000
+157% +$3.29M 2.16% 6
2023
Q1 		$2.42M Buy
354,500
+167,000
+89% +$1.3M 1.67% 12
2022
Q4 		$1.49M Buy
187,500
+134,500
+254% +$1.03M 1.47% 13
2022
Q3 		$509K Buy
+53,000
New +$536K 0.52% 55
2021
Q4 		– Sell
-35,000
Closed -$562K – 230
2021
Q3 		$562K Sell
35,000
-16,500
-32% -$242K 0.14% 63
2021
Q2 		$712K Buy
51,500
+40,500
+368% +$574K 0.19% 41
2021
Q1 		$161K Buy
11,000
+9,400
+588% +$160K 0.05% 113
2020
Q4 		$28K Hold
1,600
– – 0.01% 197
2020
Q3 		$29K Sell
1,600
-400
-20% -$7.44K 0.01% 130
2020
Q2 		$36K Buy
+2,000
New +$33.9K 0.02% 100

Other funds holding CHRS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return

AlphaCentric Advisors's CHRS Position: Q4 2024 in Review

AlphaCentric Advisors sold out of Coherus Oncology (CHRS) in Q4 2024, closing a stake of 330,000 shares — an estimated $343K sold.

AlphaCentric Advisors first reported a position in CHRS in Q2 2020 and held it in 15 quarters. The position peaked at $3.9M in Q2 2023. 124 funds tracked by Wall St. Rank hold CHRS as of Q4 2024.

  • AlphaCentric Advisors reported no remaining Coherus Oncology position as of Q4 2024 after selling out during the quarter.
  • AlphaCentric Advisors sold 330,000 Coherus Oncology shares in Q4 2024, an estimated $343K.
  • AlphaCentric Advisors first reported a position in Coherus Oncology in Q2 2020 and held it in 15 quarters.
  • AlphaCentric Advisors's Coherus Oncology position peaked at $3.9M in Q2 2023.
  • 124 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2024.

Based on AlphaCentric Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.